Published in J Lab Clin Med on June 01, 2004
A platelet-mediated system for shuttling blood-borne bacteria to CD8α+ dendritic cells depends on glycoprotein GPIb and complement C3. Nat Immunol (2011) 1.48
Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum Vaccin Immunother (2012) 1.20
Two genes on A/J chromosome 18 are associated with susceptibility to Staphylococcus aureus infection by combined microarray and QTL analyses. PLoS Pathog (2010) 1.17
Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother (2012) 1.08
Relative roles of complement factor 3 and mannose-binding lectin in host defense against infection. Infect Immun (2005) 0.95
Characterization of the mechanism of protection mediated by CS-D7, a monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB). Front Cell Infect Microbiol (2012) 0.94
Selection and characterization of murine monoclonal antibodies to Staphylococcus aureus iron-regulated surface determinant B with functional activity in vitro and in vivo. Clin Vaccine Immunol (2009) 0.91
Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice. PLoS One (2011) 0.83
Disruption of the alternative pathway convertase occurs at the staphylococcal surface via the acquisition of factor H by Staphylococcus aureus. Mol Immunol (2010) 0.81
Molecular defects in the mannose binding lectin pathway in dermatological disease: Case report and literature review. Clin Mol Allergy (2010) 0.79
Deficiency of the Complement Component 3 but Not Factor B Aggravates Staphylococcus aureus Septic Arthritis in Mice. Infect Immun (2016) 0.78
Hyperglycemia inhibits complement-mediated immunological control of S. aureus in a rat model of peritonitis. J Diabetes Res (2014) 0.78
Characterization of shark complement factor I gene(s): genomic analysis of a novel shark-specific sequence. Mol Immunol (2009) 0.76
Staphylococcal protein Ecb impairs complement receptor-1 mediated recognition of opsonized bacteria. PLoS One (2017) 0.75
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Sports medicine and ethics. Am J Bioeth (2013) 5.51
Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol (2005) 4.44
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis (2013) 4.07
Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis (2006) 3.70
Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics (2009) 3.05
Globalization of pediatric research: analysis of clinical trials completed for pediatric exclusivity. Pediatrics (2010) 2.48
Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell (2006) 2.35
Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med (2010) 2.28
Economic return of clinical trials performed under the pediatric exclusivity program. JAMA (2007) 2.28
Early predictors of in-hospital death in infective endocarditis. Circulation (2004) 2.26
Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. Obstet Gynecol (2014) 2.11
The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics (2006) 2.10
Contemporary Fontan operation: association between early outcome and type of cavopulmonary connection. Ann Thorac Surg (2012) 2.04
Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Circulation (2010) 2.01
Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters? Pediatrics (2006) 1.98
Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis (2005) 1.92
Early and late onset sepsis in late preterm infants. Pediatr Infect Dis J (2009) 1.90
Therapeutic potential of complement modulation. Nat Rev Drug Discov (2009) 1.85
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
Venous thrombosis in patients with short- and long-term central venous catheter-associated Staphylococcus aureus bacteremia. Crit Care Med (2008) 1.69
Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol (2011) 1.64
Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis (2012) 1.63
Use of the complete blood cell count in late-onset neonatal sepsis. Pediatr Infect Dis J (2012) 1.63
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis (2008) 1.62
Traumatic lumbar punctures in neonates: test performance of the cerebrospinal fluid white blood cell count. Pediatr Infect Dis J (2008) 1.55
No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants. Pediatr Infect Dis J (2015) 1.53
Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J (2012) 1.53
In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother (2004) 1.44
Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis (2006) 1.36
Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J (2005) 1.33
Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J (2009) 1.33
Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun (2005) 1.33
Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J (2011) 1.30
Value of an inhalational model of invasive aspergillosis. Med Mycol (2004) 1.29
Orbital cellulitis in children. Pediatr Infect Dis J (2006) 1.27
Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother (2012) 1.23
Neurodevelopmental outcome of extremely low birth weight infants with Candida infection. J Pediatr (2013) 1.22
Major infection after pediatric cardiac surgery: a risk estimation model. Ann Thorac Surg (2010) 1.21
Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol (2007) 1.20
Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J (2009) 1.20
Obesity, inflammation, and asthma severity in childhood: data from the National Health and Nutrition Examination Survey 2001-2004. Ann Allergy Asthma Immunol (2009) 1.19
Coagulase-negative staphylococcal infections in the neonatal intensive care unit. Infect Control Hosp Epidemiol (2011) 1.19
Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol Ther (2006) 1.18
AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol Ther (2008) 1.18
Complement levels and activity in the normal and LPS-injured lung. Am J Physiol Lung Cell Mol Physiol (2006) 1.15
Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J (2011) 1.14
Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J (2012) 1.09
Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. Pediatr Infect Dis J (2009) 1.09
Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics (2014) 1.08
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. Antimicrob Agents Chemother (2004) 1.08
In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos (2010) 1.08
A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect (2004) 1.08
Use of the complete blood cell count in early-onset neonatal sepsis. Pediatr Infect Dis J (2012) 1.07
Bypassing complement: evolutionary lessons and future implications. J Clin Invest (2006) 1.07
Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother (2010) 1.06
Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol (2015) 1.06
Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr Infect Dis J (2013) 1.06
Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J (2007) 1.05
Safety monitoring of drugs receiving pediatric marketing exclusivity. Pediatrics (2008) 1.05
A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV. AIDS (2003) 1.05
Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. Ther Drug Monit (2012) 1.04
Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. J Pediatr (2012) 1.02
Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J (2013) 1.02
Meningitis in preterm neonates: importance of cerebrospinal fluid parameters. Am J Perinatol (2008) 1.01
Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. Antimicrob Agents Chemother (2014) 1.01
Criteria supporting the study of drugs in the newborn. Clin Ther (2006) 1.00
Pediatric residents' clinical diagnostic accuracy of otitis media. Pediatrics (2002) 1.00
Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. Mol Ther (2006) 0.99
Center variation in patient age and weight at Fontan operation and impact on postoperative outcomes. Ann Thorac Surg (2011) 0.98
In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats. Drug Metab Dispos (2010) 0.98
Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J (2007) 0.97
Nosocomial infection in the NICU: a medical complication or unavoidable problem? J Perinatol (2004) 0.96
Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos (2008) 0.95
Total lymphocyte count and World Health Organization pediatric clinical stage as markers to assess need to initiate antiretroviral therapy among human immunodeficiency virus-infected children in Moshi, Northern Tanzania. Pediatr Infect Dis J (2009) 0.95
Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. Am J Infect Control (2010) 0.95
Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J (2012) 0.95
Prevention and treatment of nosocomial sepsis in the NICU. J Perinatol (2004) 0.93
Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. Biopharm Drug Dispos (2011) 0.93
Effect of sex and race on outcome in patients undergoing congenital heart surgery: an analysis of the society of thoracic surgeons congenital heart surgery database. Ann Thorac Surg (2012) 0.93
Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. Blood (2010) 0.92
Neonatal candidiasis. Infect Dis Clin North Am (2005) 0.91
The economic returns of pediatric clinical trials of antihypertensive drugs. Am Heart J (2008) 0.91
Effect of methicillin-resistant Staphylococcus aureus colonization in the neonatal intensive care unit on total hospital cost. Infect Control Hosp Epidemiol (2009) 0.90
Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J (2012) 0.90
Examination of type IV pilus expression and pilus-associated phenotypes in Kingella kingae clinical isolates. Infect Immun (2010) 0.89
Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation (2004) 0.89
Heparan sulfate, including that in Bruch's membrane, inhibits the complement alternative pathway: implications for age-related macular degeneration. J Immunol (2010) 0.89
Early sepsis does not increase the risk of late sepsis in very low birth weight neonates. J Pediatr (2013) 0.88
Group B streptococcal meningitis: cerebrospinal fluid parameters in the era of intrapartum antibiotic prophylaxis. Early Hum Dev (2009) 0.88
Risk factors and prevention of late-onset sepsis in premature infants. Early Hum Dev (2010) 0.88
Safety of micafungin in infants: insights into optimal dosing. Expert Opin Drug Saf (2011) 0.87